The FDA has specifically flagged risks including dosing errors, variable concentrations, improper storage during shipping, quality control differences, limited adverse-event reporting, and products falsely marketed for research or non-human-use purposes
Front Med 9:813083 Malewiak MI, Griglio S, Kalopissis AD, Le Liepvre X (1983) Oleate metabolism in isolated hepatocytes from lean and obese Zucker rats
Learn more about our editorial standards.
And overwhelmingly, these drugs have only been available for people who have wealth. (Obesity rates actually are slightly higher for middle-income Americans than they are for those with the lowest and highest incomes, according to 2017-2020 data collected by the US Centers for Disease Control and Prevention.) Kennedy had previously expressed skepticism about GLP-1s, but he was full of praise for Trump for pushing to help a broader segment of Americans have access to the drug
Saxenda is taken at a higher dose and approved for weight loss